SanBio revises earnings forecast as expenses climb, losses widen

SanBio Co., Ltd. announced a revision to its consolidated earnings forecast for the fiscal year ending January 31, 2026. The company now projects an ordinary loss of 4,530 million yen and a net income attributable to owners of parent loss of 4,045 million yen. This represents a significant increase in projected losses compared to its March 17, 2025 announcement. The revision is primarily attributed to non-operating expenses and deferred income taxes recorded in the first half of the fiscal year (February 1, 2025 – July 31, 2025).

During the first half, the company incurred 518 million yen in foreign exchange losses, 34 million yen in financing expenses, and 13 million yen in bond interest. Additionally, deferred income taxes of negative 485 million yen were recognized due to deferred tax liabilities associated with foreign currency-denominated loans to a consolidated subsidiary and other related receivables.

The revised forecast also incorporates increased manufacturing-related expenses to secure inventory for future clinical trials and the launch of AKUUGO. Despite these financial adjustments, SanBio continues to make progress toward the commercialization of AKUUGO. The company received conditional approval in Japan and completed a partial change application of marketing approval in June 2025, with official approval anticipated in the second half of the fiscal year ending January 2026.